Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Next Previous
Trial Profile

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir/lamivudine (Primary) ; Tenofovir alafenamide
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms ReNew

    • Most Recent Events

    • 04 Apr 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
    • 04 Apr 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.
    • 04 Apr 2019 Planned initiation date changed from 1 Sep 2018 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top